Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale for anti-OX40 cancer immunotherapy.
Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Aspeslagh S, et al. Eur J Cancer. 2016 Jan;52:50-66. doi: 10.1016/j.ejca.2015.08.021. Epub 2015 Nov 30. Eur J Cancer. 2016. PMID: 26645943 Review.
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.
Dercle L, Ammari S, Champiat S, Massard C, Ferté C, Taihi L, Seban RD, Aspeslagh S, Mahjoubi L, Kamsu-Kom N, Robert C, Marabelle A, Schlumberger M, Soria JC, Postel-Vinay S. Dercle L, et al. Among authors: aspeslagh s. Eur J Cancer. 2016 Sep;65:33-42. doi: 10.1016/j.ejca.2016.05.031. Epub 2016 Jul 21. Eur J Cancer. 2016. PMID: 27451022 Clinical Trial.
JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy.
Marabelle A, Aspeslagh S, Postel-Vinay S, Soria JC. Marabelle A, et al. Among authors: aspeslagh s. Cancer Discov. 2017 Feb;7(2):128-130. doi: 10.1158/2159-8290.CD-16-1439. Cancer Discov. 2017. PMID: 28167612
NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.
Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Pipéroglou C, Vély F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L. Rusakiewicz S, et al. Among authors: aspeslagh s. Oncoimmunology. 2016 Apr 25;6(1):e1137418. doi: 10.1080/2162402X.2015.1137418. eCollection 2017. Oncoimmunology. 2016. PMID: 28197361 Free PMC article.
84 results